Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07581405 · ClinicalTrials.gov registry record · Phase 2
GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Not yet
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT07581405 is a Phase 2 study that has not yet begun recruiting, run by University of Illinois at Chicago. The registered enrollment target is 26 participants.
The verdict
NCT07581405, a Phase 2 study, has not yet begun recruiting, sponsored by University of Illinois at Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a single-center, randomized, open-label clinical trial designed to evaluate the impact of low-dose olanzapine on weight loss, appetite, and nutritional outcomes in patients with gastric cancer receiving neoadjuvant chemotherapy. Eligible patients will be randomized to receive olanzapine 2.5 mg orally once daily (QD) in addition to standard neoadjuvant chemotherapy, beginning prior to initiation of chemotherapy and continuing until surgical resection. Patients will otherwise receive standard-of-care (SOC) oncologic treatment, with no alterations to chemotherapy regimens or surgical management. The study is designed to prospectively assess whether olanzapine improves appetite, mitigates weight loss, and enhances nutritional status and quality of life (QoL) during neoadjuvant therapy. This study will be conducted at the University of Illinois Cancer Center (UICC) as a single-site investigator-initiated trial, with an anticipated accrual of 26 participants over 2 years.
Interventions
- DRUG Olanzapine
- DRUG Neoadjuvant chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07581405
The ClinicalTrials.gov registry entry for NCT07581405 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT07581405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07581405 about?
NCT07581405 is a clinical study titled "GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer". This is a single-center, randomized, open-label clinical trial designed to evaluate the impact of low-dose olanzapine on weight loss, appetite, and nutritional outcomes in patients with gastric cancer receiving neoadjuvant chemotherapy. Eligible patients will be randomized to receive olanzapine 2.5 ...
What is the current status of trial NCT07581405?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2026-07. Estimated completion is 2030-07.
What interventions are being tested in trial NCT07581405?
The interventions under investigation include: Olanzapine (DRUG), Neoadjuvant chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07581405?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.